Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

During the Trading Day
36.15 +0.77 / +2.18%
As of 4:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
36.15 0.00 / 0.00%
 
Volume: 126.0K
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.3B

Company Description

Tetraphase Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug-resistant and gram-negative infections. The company's lead product candidate, eravacycline is a fully synthetic tetracycline derivative that is developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. It has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Contact Information

Tetraphase Pharmaceuticals, Inc.
480 Arsenal Street
Watertown Massachusetts 02472
P:(617) 715-3600
Investor Relations:
(617) 600-7040

Employees

Shareholders

Mutual fund holders40.73%
Individual stakeholders37.83%
Other institutional27.83%

Top Executives

Guy MacDonaldPresident, Chief Executive Officer & Director
John Craig ThompsonChief Operating Officer
David Charles LubnerChief Financial Officer & Senior Vice President
Patrick Taylor HornChief Medical Officer
Maria D. StahlSenior Vice President & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account